by | Apr 14, 2025 | Publications
Cancers (Basel). 2025 Mar 24;17(7):1081. doi: 10.3390/cancers17071081. ABSTRACT BACKGROUND/OBJECTIVES: In recent years, efforts by the scientific community to elucidate the underlying mechanisms of clonal expansion and selection within tumors have led to the theory of...
by | Apr 14, 2025 | Publications
Cancers (Basel). 2025 Apr 5;17(7):1235. doi: 10.3390/cancers17071235. ABSTRACT Background: Teclistamab (TEC) is the first B-cell maturation antigen-directed bispecific antibody approved in 2022 by the European Medicines Agency and Food and Drug Administration for...
by | Apr 10, 2025 | Publications
Hematol Oncol. 2025 May;43(3):e70061. doi: 10.1002/hon.70061. ABSTRACT Daratumumab in combination with lenalidomide and dexamethasone (DRd) and bortezomib in combination with lenalidomide and dexamethasone (VRd) are guideline-recommended preferred regimens for initial...
by | Apr 10, 2025 | Myeloma News
Source: Pharmacy Times articles Erin Harrell, PharmD, offers insights about managing peripheral neuropathy in patients receiving bortezomib. Read More
by | Apr 10, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
